| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(202)_ICD10(M058) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Other seropositive rheumatoid arthritis | 2290 | |
| REIMB | REIMB_KELA(202)_ICD10(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis | 2073 | |
| REIMB | REIMB_KELA(313)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Other seropositive rheumatoid arthritis | 1390 | |
| REIMB | REIMB_KELA(281)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Other seropositive rheumatoid arthritis | 1285 | |
| REIMB | REIMB_KELA(313)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis | 977 | |
| REIMB | REIMB_KELA(281)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis | 833 | |
| REIMB | REIMB_KELA(202)_ICD10(M059) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis, unspecified | 223 | |
| REIMB | REIMB_KELA(3006)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 130 | |
| REIMB | REIMB_KELA(291)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 123 | |
| REIMB | REIMB_KELA(293)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 121 | |
| REIMB | REIMB_KELA(3005)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 76 | |
| REIMB | REIMB_KELA(293)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 71 | |
| REIMB | REIMB_KELA(291)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 70 | |
| REIMB | REIMB_KELA(3006)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 69 | |
| REIMB | REIMB_KELA(313)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis, unspecified | 55 | |
| REIMB | REIMB_KELA(3005)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 51 | |
| REIMB | REIMB_KELA(281)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis, unspecified | 48 | |
| REIMB | REIMB_KELA(298)_ICD10(M058) | Name not found, Other seropositive rheumatoid arthritis | 24 | |
| REIMB | REIMB_KELA(3029)_ICD10(M05) | Upadacitinib, Seropositive rheumatoid arthritis | 23 | |
| REIMB | REIMB_KELA(3029)_ICD10(M058) | Upadacitinib, Other seropositive rheumatoid arthritis | 23 | |
| REIMB | REIMB_KELA(298)_ICD10(M05) | Name not found, Seropositive rheumatoid arthritis | 22 | |
| REIMB | REIMB_KELA(202)_ICD9(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 10 | |
| REIMB | REIMB_KELA(202)_ICD10(M056) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 6 | |
| REIMB | REIMB_KELA(313)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Felty's syndrome | 6 | |
| REIMB | REIMB_KELA(281)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Felty's syndrome | 5 | |
| REIMB | REIMB_KELA(3048)_ICD10(M058) | Name not found, Other seropositive rheumatoid arthritis | 5 |